{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T19:43:28Z","timestamp":1791229408202,"version":"4.1.0"},"reference-count":36,"publisher":"Wiley","issue":"5","license":[{"start":{"date-parts":[[2025,8,8]],"date-time":"2025-08-08T00:00:00Z","timestamp":1754611200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004336","name":"Novartis","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004336","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Hematological Oncology"],"published-print":{"date-parts":[[2025,9]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n                  <jats:p>Treatment\u2010free remission (TFR) in chronic myeloid leukemia (CML) can be considered for patients in sustained deep molecular response (DMR) who can discontinue tyrosine kinase inhibitors (TKIs) while maintaining responses. Studies suggest that TKI de\u2010escalation before TFR is feasible. This phase II study evaluated nilotinib de\u2010escalation outcomes in adults with CML in chronic phase (CP) treated with first\u2010line nilotinib for \u2265\u00a03\u00a0years and in sustained DMR for \u2265\u00a01\u00a0year. The study had four phases: screening, de\u2010escalation (week 0\u201348), TFR (week 48\u2013144) and follow\u2010up. During de\u2010escalation, patients received nilotinib 300\u00a0mg once daily, and those with sustained DMR entered TFR and discontinued nilotinib. Patients with major molecular response (MMR) but without sustained DMR continued nilotinib. At the data cut\u2010off, 107 patients entered, and 98 (91.6%) completed de\u2010escalation. TFR was entered by 90 patients (84.1%) with sustained DMR. At 96\u00a0weeks, 71\/107 patients (66.4%) were in full TFR; 64\/90 patients (71.1%) who entered TFR remained in \u2265\u00a0MMR, and the median time\u2010to\u2010loss of MMR was not reached. During TFR, adverse events occurred in 64 patients (71.1%), including one serious event (pneumonia). Our data suggest that the de\u2010escalation of nilotinib before a TFR attempt in CML\u2010CP patients with sustained DMR can be a successful dose optimization strategy.<\/jats:p>","DOI":"10.1002\/hon.70126","type":"journal-article","created":{"date-parts":[[2025,8,8]],"date-time":"2025-08-08T11:19:56Z","timestamp":1754651996000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Treatment\u2010Free Remission in Chronic Phase Chronic Myeloid Leukemia After Nilotinib De\u2010Escalation: 96\u2010Week Update of the DANTE Study"],"prefix":"10.1002","volume":"43","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4401-0812","authenticated-orcid":false,"given":"Alessandra","family":"Iurlo","sequence":"first","affiliation":[{"name":"Hematology Division Foundation IRCCS Ca' Granda Ospedale Maggiore Policlinico  Milan Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1163-6162","authenticated-orcid":false,"given":"Massimo","family":"Breccia","sequence":"additional","affiliation":[{"name":"Hematology Department of Translational and Precision Medicine Policlinico Umberto I Sapienza University  Rome Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7947-158X","authenticated-orcid":false,"given":"Fabio","family":"Stagno","sequence":"additional","affiliation":[{"name":"Hematology Unit AOU Policlinico \u201cG. Martino\u201d University of Messina  Messina Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5228-6491","authenticated-orcid":false,"given":"Elisabetta","family":"Abruzzese","sequence":"additional","affiliation":[{"name":"Hematology S. Eugenio Hospital, Tor Vergata University, ASL Roma 2  Rome Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2563-4125","authenticated-orcid":false,"given":"Fabrizio","family":"Pane","sequence":"additional","affiliation":[{"name":"Department of Clinical Medicine and Surgery Federico II University of Naples  Naples Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3527-3151","authenticated-orcid":false,"given":"Immacolata","family":"Attolico","sequence":"additional","affiliation":[{"name":"Department of Emergency and Organ Transplantation (D.E.T.O.) University of Bari Hematology Section  Bari Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5630-9862","authenticated-orcid":false,"given":"Paolo","family":"Sportoletti","sequence":"additional","affiliation":[{"name":"Centro di Ricerca Emato\u2010Oncologica (CREO) University of Perugia  Perugia Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1666-3100","authenticated-orcid":false,"given":"Marco","family":"Cerrano","sequence":"additional","affiliation":[{"name":"Hematology Unit Azienda Ospedaliero\u2010Universitaria Citt\u00e0 della Salute e della Scienza  Turin Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7899-5966","authenticated-orcid":false,"given":"Sara","family":"Galimberti","sequence":"additional","affiliation":[{"name":"Department of Clinical and Experimental Medicine Hematology Section University of Pisa  Pisa Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4162-0009","authenticated-orcid":false,"given":"Barbara","family":"Scappini","sequence":"additional","affiliation":[{"name":"Hematology AOU Careggi University of Florence  Florence Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-6577-2388","authenticated-orcid":false,"given":"Maurizio","family":"Miglino","sequence":"additional","affiliation":[{"name":"Hematology Clinic IRCCS San Martino Hospital  Genoa Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1641-6508","authenticated-orcid":false,"given":"Sergio","family":"Siragusa","sequence":"additional","affiliation":[{"name":"Pro.Mi.Se Department University of Palermo  Palermo Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-7853-3310","authenticated-orcid":false,"given":"Isabella","family":"Capodanno","sequence":"additional","affiliation":[{"name":"Hematology Department Azienda Unit\u00e0 Sanitaria Locale\u2010IRCCS di Reggio Emilia  Reggio Emilia Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diletta","family":"Valsecchi","sequence":"additional","affiliation":[{"name":"Novartis Farma SpA  Milan Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-2282-1990","authenticated-orcid":false,"given":"Aurelio Pio","family":"Nardozza","sequence":"additional","affiliation":[{"name":"Novartis Farma SpA  Milan Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandra","family":"Misto","sequence":"additional","affiliation":[{"name":"Novartis Farma SpA  Milan Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paola","family":"Coco","sequence":"additional","affiliation":[{"name":"Novartis Farma SpA  Milan Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1046-3514","authenticated-orcid":false,"given":"Giuseppe","family":"Saglio","sequence":"additional","affiliation":[{"name":"Department of Clinical and Biological Sciences University of Turin  Turin Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0310-4206","authenticated-orcid":false,"given":"Gianantonio","family":"Rosti","sequence":"additional","affiliation":[{"name":"IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) \u201cDino Amadori\u201d  Meldola Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2025,8,8]]},"reference":[{"key":"e_1_2_10_2_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clml.2015.02.035"},{"key":"e_1_2_10_3_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.blre.2021.100825"},{"key":"e_1_2_10_4_1","volume-title":"Statpearls. Treasure Island FL","author":"Eden R. E.","year":"2024"},{"key":"e_1_2_10_5_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00277\u2010015\u20102314\u20102"},{"key":"e_1_2_10_6_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41408\u2010023\u201000823\u20109"},{"key":"e_1_2_10_7_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2015.66.2866"},{"key":"e_1_2_10_8_1","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2013.52.9123"},{"key":"e_1_2_10_9_1","doi-asserted-by":"publisher","DOI":"10.1182\/asheducation\u20102016.1.170"},{"key":"e_1_2_10_10_1","doi-asserted-by":"publisher","DOI":"10.1016\/s2352\u20103026(18)30051\u20106"},{"key":"e_1_2_10_11_1","doi-asserted-by":"publisher","DOI":"10.1002\/hon.3309"},{"key":"e_1_2_10_12_1","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.769730"},{"key":"e_1_2_10_13_1","doi-asserted-by":"publisher","DOI":"10.3390\/jcm11071801"},{"key":"e_1_2_10_14_1","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2016.68.2914"},{"key":"e_1_2_10_15_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood\u20102016\u201009\u2010742205"},{"key":"e_1_2_10_16_1","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2012.48.5797"},{"key":"e_1_2_10_17_1","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2017.63"},{"key":"e_1_2_10_18_1","doi-asserted-by":"publisher","DOI":"10.1016\/s2352\u20103026(19)30094\u20108"},{"key":"e_1_2_10_19_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2017.02.028"},{"key":"e_1_2_10_20_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41375\u2010021\u201001205\u20105"},{"key":"e_1_2_10_21_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41375\u2010020\u20100776\u20102"},{"key":"e_1_2_10_22_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41375\u2010020\u201001111\u20102"},{"key":"e_1_2_10_23_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood\u20102007\u201004\u2010083196"},{"key":"e_1_2_10_24_1","unstructured":"Novartis.Tasigna Summary of Product Characteristics (2012). Accessed April 29 2024 https:\/\/www.ema.europa.eu\/en\/documents\/product\u2010information\/tasigna\u2010epar\u2010product\u2010information_en.pdf."},{"key":"e_1_2_10_25_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood\u20102022\u2010157700"},{"key":"e_1_2_10_26_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.v128.22.787.787"},{"key":"e_1_2_10_27_1","doi-asserted-by":"publisher","DOI":"10.1016\/s1470\u20102045(18)30192\u2010x"},{"key":"e_1_2_10_28_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.v124.21.4547.4547"},{"issue":"4","key":"e_1_2_10_29_1","first-page":"893","article-title":"Why are Not all Eligible Chronic Myeloid Leukemia Patients Willing to Attempt Tyrosine Kinase Inhibitor Discontinuation? A Czech Nationwide Analysis Related to the TKI Stopping Trial HALF","volume":"38","author":"\u017d\u00e1\u010dkov\u00e1 D.","year":"2024","journal-title":"Leukemia"},{"key":"e_1_2_10_30_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41375\u2010020\u20100867\u20100"},{"key":"e_1_2_10_31_1","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.32940"},{"key":"e_1_2_10_32_1","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.25908"},{"key":"e_1_2_10_33_1","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2023.1154377"},{"issue":"1","key":"e_1_2_10_34_1","first-page":"333","article-title":"EP751. Efficacy and Safety of Nilotinib in Chronic Myeloid Leukaemia Patients Who Failed to Achieve a Treatment\u2010free Remission Period After Imatinib Discontinuation: Results of the French NILO POST\u2010STIM Study. 25th Congress of the European Hematology Association Virtual Edition, 2020","volume":"4","author":"Dulucq S.","year":"2020","journal-title":"HemaSphere"},{"key":"e_1_2_10_35_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood\u20102019\u2010123719"},{"key":"e_1_2_10_36_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood\u20102018\u201099\u2010114656"},{"key":"e_1_2_10_37_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood\u20102020\u2010143816"}],"container-title":["Hematological Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/hon.70126","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,16]],"date-time":"2025-10-16T11:03:36Z","timestamp":1760612616000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/hon.70126"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,8]]},"references-count":36,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2025,9]]}},"alternative-id":["10.1002\/hon.70126"],"URL":"https:\/\/doi.org\/10.1002\/hon.70126","archive":["Portico"],"relation":{},"ISSN":["0278-0232","1099-1069"],"issn-type":[{"value":"0278-0232","type":"print"},{"value":"1099-1069","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,8,8]]},"assertion":[{"value":"2025-03-24","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-08-03","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-08-08","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e70126"}}